EGFR and glioblastoma: This case highlights the heterogeneity of this tumor, which is still a major challenge for EGFR-targeted GBM therapy, together with the limited brain permeability of most TKIs and the low specificity of small molecules inhibiting GBM-related EGFR mutations [14].